Explainer
We monitor community discourse because readers encounter it, but we do not help people buy, dose, or use peptides. These guidelines establish what is and is not allowed in community discussions on this site — in comments, submitted reviews, survey responses, forum threads, and any other reader-contributed content. The boundaries exist for safety, legal, and editorial-integrity reasons, and they apply equally to readers, contributors, and moderators. The goal is to keep the community useful for critical reading and source evaluation without turning it into a sourcing, dosing, or how-to-use channel.
Peptides sit in a regulatory gray zone. Most compounds discussed online are not FDA-approved for their popular uses, many are sold through research-use-only (RUO) channels that carry no clinical oversight, and the public information landscape mixes peer-reviewed evidence, regulatory records, expert commentary, and unverified community claims. In that environment, community discussion can either help readers evaluate claims critically or amplify unsafe, illegal, or misleading guidance. These guidelines exist to keep discourse on the helpful side of that line. Three concerns shape the rules: reader safety, legal exposure, and editorial integrity. Safety, because dosing and route-of-use guidance can cause direct harm when the underlying products are unregulated and poorly characterized. Legal, because dosing instructions, vendor recommendations, and 'safe for personal use' claims contradict the research-use-only designation the FDA has cited in warning letters. Editorial integrity, because a site that claims to be an information index cannot simultaneously host purchasing or treatment guidance without misrepresenting what it is.
FDA guidance on labeling requirements for Research Use Only (RUO) and Investigational Use Only (IUO) products, clarifying that RUO/IUO designations do not exempt products from FDA enforcement if therapeutic claims or human-use marketing is present.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
FDA warning letters database showing enforcement actions against online peptide sellers who market products as research-use-only while making therapeutic claims, providing dosing guidance, or implying human use. Includes warning letters to Gram Peptides and others in the peptide space.
Community discussion is welcome when it helps readers evaluate claims, locate public sources, and understand the regulatory landscape. The allowed categories below are deliberately framed around critical reading and source verification, not around personal use. A useful question for contributors is: does this help someone read more carefully, or does it help someone use a compound? If it does the former, it belongs here; if it does the latter, it does not.
FDA's MedWatch program for reporting adverse events, product quality problems, and medication errors related to FDA-regulated products including compounded drugs. Voluntary for consumers, mandatory for certain healthcare entities. There is no equivalent reporting system for RUO-sourced products.
FDA warning letters database showing enforcement actions against online peptide sellers who market products as research-use-only while making therapeutic claims, providing dosing guidance, or implying human use. Includes warning letters to Gram Peptides and others in the peptide space.
The following content is removed on sight, regardless of how it is phrased. These boundaries exist because the listed content either constitutes treatment guidance, facilitates purchasing, or makes safety claims that contradict the regulatory status of the products discussed. The list is exhaustive for the most common violation categories; moderators may also remove content that, while not listed verbatim, serves the same function.
FDA guidance on labeling requirements for Research Use Only (RUO) and Investigational Use Only (IUO) products, clarifying that RUO/IUO designations do not exempt products from FDA enforcement if therapeutic claims or human-use marketing is present.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
FDA's MedWatch program for reporting adverse events, product quality problems, and medication errors related to FDA-regulated products including compounded drugs. Voluntary for consumers, mandatory for certain healthcare entities. There is no equivalent reporting system for RUO-sourced products.
Moderation is applied to the content, not to the person. The goal is to keep discourse within the allowed categories, not to penalize readers who may not yet know where the lines are. The sequence below describes how a typical violation is handled. Repeated or willful violations, particularly those that reframe dosing or sourcing guidance after removal, result in loss of posting privileges.
How to evaluate marketplace listings, vendor claims, and red flags without buying.
How the index stays current: source records, review dates, and the refresh log.
The parent hub comparing research-use-only suppliers and telehealth prescribing channels.
A structured checklist for assessing supplier documentation quality and FDA enforcement history.
Chronological record of FDA actions against peptide sellers.
Full list of tracked FDA, peer-reviewed, and community sources backing this page.
Free report
A practical checklist for reviewing RUO supplier pages, telehealth pages, supplies, and operator-stack claims without confusing the regulatory lane.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
This explainer is informational. It does not recommend one access path over another, provide medical advice, or evaluate whether any compound is appropriate for human use. Both paths carry risks, and most peptides discussed online lack sufficient human clinical trial data for their popular uses.
Source records are stored in the repo and linked from each section.
FDA guidance on labeling requirements for Research Use Only (RUO) and Investigational Use Only (IUO) products, clarifying that RUO/IUO designations do not exempt products from FDA enforcement if therapeutic claims or human-use marketing is present.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
FDA warning letters database showing enforcement actions against online peptide sellers who market products as research-use-only while making therapeutic claims, providing dosing guidance, or implying human use. Includes warning letters to Gram Peptides and others in the peptide space.
FDA's MedWatch program for reporting adverse events, product quality problems, and medication errors related to FDA-regulated products including compounded drugs. Voluntary for consumers, mandatory for certain healthcare entities. There is no equivalent reporting system for RUO-sourced products.